Dr Charles Vega believes that primary care will be the chief clinical setting for application of new blood-based biomarkers.
We asked Dr. Joanne Pike, CEO of the Alzheimer's Association to help explain the challenges and hopes when it comes to this debilitating disease.
Dementia is a collective term for various conditions that cause progressive brain decline and memory loss, with Alzheimer's ...
Hosted on MSN1h
TYK2 enzyme alters tau protein that contributes to Alzheimer's disease, researchers discover"Many studies have shown that the accumulation of tau in neurons and glial cells in the brain is a main characteristic of ...
Nearly 3,000 people participated in the Walk to End Alzheimer’s in Richmond on Saturday, Nov. 9, and it’s close to reaching its donation goal, which goes to furthering the care, ...
According to the U.S. Department of Veterans Affairs, veterans are more likely to develop Alzheimer's disease and other ...
Panax ginseng shows highest effectiveness in treating Alzheimer's. Learn more about AVXL's blarcamesine and SAVA's simufilam ...
A study of cells from 84 brains finds that Alzheimer's has two distinct phases, and that one type of neuron is especially ...
Understanding Alzheimer’s and the Role of Clinical Trials Clinical trials for Alzheimer’s are transforming the landscape of treatment and support for those living with this challenging condition. With ...
With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...
A brain mapping study funded by the NIH reveals which cell types may be the first to be affected. New research funded by the ...
Here are 10 healthy habits for our brain suggested by the Alzheimer’s Association. Challenge your mind. Learn something new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback